STAT

The new coronavirus can likely remain airborne for some time. That doesn’t mean we’re doomed

Evidence suggests the new #coronavirus #Covid19 can exist as an aerosol only under very limited conditions, and this transmission route is not driving the pandemic.
Source: Elaine Cromie/Getty Images

When a new virus blasts out of the animals that harbored it and into people, experts can usually say, thank goodness it’s not like measles. That virus is more contagious than any others known to science: Each case of measles causes an astronomical 12 to 18 new cases, compared to about six for polio, smallpox, and rubella. Each case of the new coronavirus is estimated to cause two to three others.

The reason the measles is so, well, viral, is that the microbe is so small and hardy that it is able to stay suspended in the air where an infected person coughed or sneezed for up to two hours, making it one of the only viruses that can exist as a true aerosol.

Now there are conflicting reports on whether the new coronavirus can. The studies suggesting that it can be aerosolized are only preliminary, and other research contradicts it, finding no aerosolized coronavirus particles in the hospital rooms of Covid-19 patients.

The weight of the evidence suggests that the new coronavirus can exist

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks